TherapeuticsMD (NASDAQ:TXMD) Stock Falls 1.6% – Here’s What Happened

TherapeuticsMD, Inc. (NASDAQ:TXMD)’s share price was down 1.6% during trading on Friday. The company traded as low as $1.80 and last traded at $1.80. 3,832 shares traded hands during mid-day trading, a decline of 81% from the average session volume of 20,304 shares. The stock had previously closed at $1.83.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of TherapeuticsMD from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Wednesday, August 26th. One research analyst has rated the stock with a Sell rating. Based on data from MarketBeat.com, TherapeuticsMD presently has a consensus rating of “Sell”.

TherapeuticsMD Stock Performance

The firm has a market cap of $20.83 million, a price-to-earnings ratio of 90.00 and a beta of 0.65. The business has a fifty day moving average of $2.05 and a two-hundred day moving average of $2.12.

TherapeuticsMD (NASDAQ:TXMD) last released its quarterly earnings data on Tuesday, August 11th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($6.12) by $6.13. The firm had revenue of $0.87 million during the quarter, compared to the consensus estimate of $19.77 million. TherapeuticsMD had a negative return on equity of 1.09% and a negative net margin of 6.64%.

Institutional Investors Weigh In On TherapeuticsMD

A hedge fund recently raised its stake in TherapeuticsMD stock. Renaissance Technologies LLC boosted its holdings in shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) by 51.5% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 146,200 shares of the company’s stock after acquiring an additional 49,700 shares during the period. Renaissance Technologies LLC owned about 1.26% of TherapeuticsMD worth $295,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc was a pharmaceutical company focused on developing and commercializing products for women’s health. Its portfolio addressed contraception, menopause-related conditions, pregnancy-related nausea, and nutritional support, with products marketed primarily in the United States.

The company’s principal products included ANNOVERA, a reusable, year-long vaginal contraceptive system; IMVEXXY, vaginal inserts containing estradiol for the treatment of moderate to severe vaginal symptoms associated with menopause; and BIJUVA, an oral hormone therapy combining estradiol and progesterone.